Howard Kaufman

Howard Kaufman was instrumental in the clinical development of T-VEC (talimogene laherparepvec), the first FDA-approved oncolytic virus immunotherapy for intratumoral injection in melanoma. His clinical trials established that intratumoral oncolytic virus therapy can generate both local and systemic anti-tumor immunity. He continues to advance next-generation intratumoral oncolytic virus combinations with checkpoint inhibitors.